GlassScriptPhysician profile
Anthony J Gunn
NPI 1194718288
$9,310.48
in general payments reported to CMS, 2019-2025
67 companies · $1,460 in 2025
The $1,460 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,335 · 2020: $648 · 2021: $1,633 · 2022: $1,431 · 2023: $1,306 · 2024: $1,498 · 2025: $1,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,263.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,528.59 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $837.61 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $789.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $660.20 | 2019-2023 | |
| Antares Pharma, INC. | $465.39 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Pfizer INC. | $398.79 | 2019-2025 | |
| Lilly USA, LLC | $365.00 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $353.77 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sumitomo Pharma America, INC. | $320.25 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $258.94 | 2019-2025 | |
| Astellas Pharma US INC | $232.20 | 2019-2025 | Veozah, Myrbetriq |
| Supernus Pharmaceuticals, INC. | $216.60 | 2019-2023 | Tlando, Xyosted, Qelbree |
| Amgen INC. | $207.54 | 2019-2022 | |
| Amarin Pharma, INC. | $183.00 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $181.64 | 2024-2025 | Caplyta |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Gunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.